2019 AGENDA

Thursday, April 25, 2019
8:00 AM - 8:30 AM
Welcome Coffee and Networking
8:30 AM - 8:40 AM
Chairman's Opening Address
 
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox
8:40 AM - 9:00 AM
Section 101: Are We on The Other Side of the Looking-Glass?
David Gindler, Managing Partner, Irell & Manella
9:00 AM - 9:30 AM
US Patent Prosecution & Protection Outlook
  • The Likely Forward Direction of the US Supreme Court 
  • Recent Case Law Round-up: Hearings, Outcomes, Highlights and Lowlights
  • Hatch-Waxman: Implications and Considerations
  • Bayh Dole: Implications and Considerations
  • Is the Inter Partes Review Process Sufficiently Balanced?
Moderator: 
Ha Kung Wong, Partner, Venable Fitzapatrick
 
Panellists:
Ahmed Mousa, Vice President, General Counsel & Corporate Secretary, Pieris Pharmaceuticals
John Kirkland ,Director, Intellectual Property, Alkermes
9:30 AM - 9:50 AM

The Future European Patent Landscape 

  • Where are we at Present and to Where are we Carving a Path?      
  • Latest on the Unified Patent Court and the Unitary Patent System
  • Ideas on Brexit Anyone?
  • Supplementary Protection Certificates Status Overview
Michael Pears, Partner, Biotechnology Patent Department, Potter Clarkson
Nick McDonald, Partner, Dispute Resolution and Commercial Department, Potter Clarkson
9:50 AM - 10:05 AM

Protection of Antibodies in China  

Gesheng Huang, Partner, Zhongi Law Office
10:05 AM - 10:35 AM

Best Practice In Patenting Precision Medicine 

  • What are the likely precision medicine implications of the Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd. decision in 2018?
  • How might the Advancing Access to Precision Medicine (H.R. 5062), 21st Century Cures and Verifying Accurate, Leading-edge IVCT Development (VALID) Acts, encourage/impact the patent precision medicine landscape?
  • Should the patent eligibility of diagnostic method claims and primer tools issue of the Roche Molecular Systems, Inc. v Cepheid decision be revisited?
  • Will the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics decision continue to limit the patentability of inventions based on products found in nature?
  • What are possible strategies to successfully patent artificial intelligence-based inventions for precision medicine?
Moderator:
Brian Slater, Partner and Chair of Life Sciences, Pierce Bainbridge
 
Panellists: 
John Sninsky, Chief Scientific Officer, CareDx
Shilpi Banerjee, Chief Intellectual Property Counsel, Memorial Sloan Kettering Cancer Center
Conor McDonough, Partner, Pierce Bainbridge
10:35 AM - 11:00 AM

Morning Coffee and Networking in the Exhibition Hall

11:00 AM - 11:30 AM
Biologics and Biosimilars
 
  • Why do the Differences Between Biosimilars and Generics Matter?
  • Do Biologics Necessitate Date Exclusivity Protection?
  • How do we Ensure Effective Protection for Antibodies?
Moderator:
Rolando Medina, Partner, Choate Hall & Stewart
 
Panellists:
Atsuko Polzin, Vice President, Intellectual Property, Scholar Rock
Meg Ives, Partner, Choate Hall & Stewart
Eileen Falvey, Senior Counsel, Biologics Patents U.S., Sanofi
11:30 AM - 11:50 AM

Supplementary Protection Certificates: What you need to know to take advantage of CSPs in Canada?

Beverley Moore, Partner, Borden Ladner Gervais
11:50 AM - 12:10 PM

Canadian Patent Year in Review and Future Perspective

  • NAFTA 2.0
  • Budget Implementation Act, 2018, No. 2
  • New Patent Rules
  • Notable Patent Cases of 2018
  • Canadian Pharma Developments
David Schwartz, Partner, Smart & Biggar
Yoon Kang, Partner, Smart & Biggar
12:10 PM - 12:30 PM

Plausibility: The threshold for assessing validity of life science patents - a European perspective

- Plausibility is not a ground of invalidity under the EPC. However, it increasingly has a role in the assessment of:
 
- Priority
- Industrial application
- Obviousness
- Sufficiency
  • What is the threshold for plausibility and is the right balance being struck?
  • Is data required in the application?
  • Recent court/EPO guidance, including the UK Supreme Court in Warner-Lambert v Actavis (2018)
Zoë Butler, Partner, Powell Gilbert
Penny Gilbert, Partner, Powell Gilbert
12:30 PM - 12:45 PM

Significant Recent Life Sciences Decisions Round Up- IPRS, District Courts

Arlene Chow, Partner, Hogan Lovell

12:45 PM - 1:30 PM

Lunch and Networking In The Exhibition Hall

1:35 PM - 1:40 PM
Roundtable Discussion Groups 
Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 45 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all six topics.
1:45 PM - 2:30 PM

IP considerations in Personalised Medicine

Brian Slater, Partner and Chair of Life Sciences, Pierce Bainbridge

Conor McDonough, Partner, Pierce Bainbridge

1:45 PM - 2:30 PM

BREXIT: Pragmatic steps for your portfolio, and considerations effect of the SPC & UPC

Sally Shorthose, Partner, Bird & Bird

Patrick Kelleher, Partner, Bird & Bird

1:45 PM - 2:30 PM

Navigating the CRISPR patent and licensing landscape

Claire Irvine, HGF, Partner

1:45 PM - 2:30 PM

How do we Ensure Effective Protection of Antibodies?

Filko Prugo, Partner, Chair of Life Sciences IP Litigation, Ropes & Gray

Charlotte Jacobsen, Partner, Ropes & Gray 

1:45 PM - 2:30 PM

Supplementary Protection Certificates

Beverley Moore
Partner - Intellectual Property
Borden Ladner Gervais
1:45 PM - 2:30 PM

Latest developments in US post-grant proceedings

Anita Varma, Partner, White & Case

1:45 PM - 2:30 PM
Strategies in second medical use cases

Emily Hayes, Mewburn Ellis, Partner

Nick Sutcliffe, Mewburn Ellis, Partner

1:45 PM - 2:30 PM

CAR-T and other Immunotherapies

Lin Hymel, Arent Fox, Partner

1:45 PM - 2:30 PM

Life Sciences Patents Open Clinic: Solving in-house counsel challenges

John Serio, Partner, Burns Levinson
Christopher Cowles, Partner, Burns Levinson
Richard Emmons, Partner, Burns Levinson
1:45 PM - 2:30 PM
Biologics & Biosimilars
 
Mark Izraelewicz, Partner, Marshall Gerstein & Borun
2:30 PM - 3:15 PM

Life Sciences Patents Open Clinic: Solving in-house counsel challenges

John Serio, Partner, Burns Levinson
Christopher Cowles, Partner, Burns Levinson
Richard Emmons, Partner, Burns Levinson
2:30 PM - 3:15 PM

IP considerations in Personalised Medicine

Brian Slater, Partner and Chair of Life Sciences, Pierce Bainbridge

Conor McDonough, Partner, Pierce Bainbridge

2:30 PM - 3:15 PM
Strategies in second medical use cases
 
Emily Hayes, Mewburn Ellis, Partner
Nick Sutcliffe, Mewburn Ellis, Partner
2:30 PM - 3:15 PM

Supplementary Protection Certificates

Beverley Moore 
Partner - Intellectual Property 
Borden Ladner Gervais
2:30 PM - 3:15 PM

Navigating the CRISPR patent and licensing landscape

Claire Irvine, HGF, Partner

2:30 PM - 3:15 PM

Latest developments in US post-grant proceedings

Anita Varma, Partner, White & Case

2:30 PM - 3:15 PM

How do we Ensure Effective Protection of Antibodies?

Filko Prugo, Partner, Chair of Life Sciences IP Litigation, Ropes & Gray

Charlotte Jacobsen, Partner, Ropes & Gray 

2:30 PM - 3:15 PM
Biologics & Biosimilars
 
Mark Izraelewicz, Partner, Marshall Gerstein & Borun
2:30 PM - 3:15 PM

CAR-T and other Immunotherapies

Lin Hymel, Arent Fox, Partner

2:30 PM - 3:15 PM

BREXIT: Pragmatic steps for your portfolio, and considerations effect of the SPC & UPC

Sally Shorthose, Partner, Bird & Bird

Patrick Kelleher, Partner, Bird & Bird

3:15 PM - 3:30 PM
Key Findings and Points of Note
3:30 PM - 4:00 PM
Afternoon Tea and Networking in the Exhibition Hall
4:00 PM - 4:30 PM

Addressing Second Medical Use Infringement

  • Recent Key Cases and Overview of Varying Jurisdictions
  • Why we need Global Harmonisation of Patentability
  • What must Generic Manufacturers do where a Second Medical Use Patent is in Force?
  • What Practical Steps must a Second Medical Use Patent Owner take when Infringement is Suspected?
Moderator:
Sarah Columbia, Partner, McDermott, Will & Emery
 
Panellists:
Shahan Islam, Senior Patent Counsel, Pfizer
Mary Morry, Counsel, Merck Sharp & Dohme
4:30 PM - 4:50 PM

A Review of Recent Judgements

  • How can parties utilise this litigation tool?
  • When is the relief likely to be useful?
Paul Inman, Partner, Gowling WLG
4:50 PM - 5:20 PM

IP Portfolio Management: In-house Counsel Day-to-Day Challenges in Prosecuting and Enforcing Patents

Moderator:

Chad Davis, Partner, Dechert

Panellists:

Danielle Abramson, VP Intellectual Property & Research, RedHill Biopharma
Atabak Royaee, Associate Director & Senior Counsel, IP & EHS, Boehringer Ingelheim Pharmaceuticals
James Harrington, Senior Vice President - Intellectual Property, Takeda
5:20 PM
Chairman's Closing Remarks & Networking Drinks
 
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox